



Tepezza™ (teprotumumab-trbw) – New orphan drug approval

- On January 21, 2020, the [FDA announced](#) the approval of [Horizon Therapeutics' Tepezza \(teprotumumab-trbw\)](#), for the treatment of thyroid eye disease (TED).
- TED is a progressive and vision-threatening rare autoimmune disease. TED is associated with the outward bulging of the eye (proptosis) that can cause a variety of symptoms such as eye pain, double vision, light sensitivity or difficulty closing the eye.
- Tepezza is an insulin-like growth factor-1 receptor inhibitor (IGF-1R). The mechanism of action in patients with TED has not been fully characterized.
- Tepezza was evaluated in two randomized, double-masked, placebo-controlled studies in 171 patients with TED. Patients were given intravenous (IV) infusions every 3 weeks for a total of 8 infusions. The proptosis responder rate at week 24 was defined as the percentage of patients with ≥ 2 mm reduction in proptosis in the study eye from baseline, without deterioration in the non-study eye (≥ 2 mm increase) in proptosis.
 - In study 1, the proptosis responder rate was 71% and 20% with Tepezza and placebo, respectively (difference: 51, 95% CI: 33, 69).
 - In study 2, the proptosis responder rate was 83% and 10% with Tepezza and placebo, respectively (difference: 73, 95% CI: 59, 88).
- Warnings and precautions for Tepezza include infusion reactions, exacerbation of inflammatory bowel disease, and hyperglycemia.
- The most common adverse reactions ($> 5\%$) with Tepezza use were muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dry skin, dysgeusia and headache.
- The recommended dose of Tepezza is 10 mg/kg for the first IV infusion, followed by 20 mg/kg every 3 weeks for 7 additional infusions.
- Horizon Therapeutics plans to launch Tepezza in the coming weeks. Tepezza will be available as a 500 mg lyophilized powder in a single-dose vial for reconstitution



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.